Thalidomide embryopathy has been diagnosed by ultrasound examination at 17 weeks gestation . Facial abnormalities include microtia, facial palsy, orofacial cleft and microphtalmia.
Cardiac malformations range from ventricular or atrial septal defect to conotruncal defects.
Poor fetal growth, urogenital, gastrointestinal and spinal defects may occur . Exclusion of fetal anomalies not associated with thalidomide exposure. Dependant on the severity of fetal malformation. Recent use in the U.S. market has raised concern about exposure to pregnancy. No safe dose of thalidomide treatment during the critical period has been established.